1 Asymptomatic COVID-19 positive patients. <br/ >2 Patient with ordinal scale of â?¥4 <br/ >3 On Tube feeding or parenteral nutrition. <br/ >4 Admission to isolation ward or hospitalization >48hrs of confirmed COVID-19 positive test. <br/ >5 Patients on ventilator support. <br/ >6 Patients with uncontrolled, unstable comorbidities <br/ >7 Pre-existing or diagnostic history with chronic lung disease, active malignancy, chronic kidney disease, chronic liver disease. <br/ >8 History of allergic reactions or anaphylaxis to investigational product components. <br/ >9 Patients participation in any another study including macro/micro/any other forms of dietary supplements/multivitamins or oral nutrition supplements. <br/ >10 Patients who are Immunocompromised or those on immunosuppressants <br/ >11 Pregnant and lactating females <br/ >12 Any other condition which the principal investigator thinks may jeopardize the safety of subjects.

1 Asymptomatic COVID-19 positive patients. <br/ >2 Patient with ordinal scale of â?¥4 <br/ >3 On Tube feeding or parenteral nutrition. <br/ >4 Admission to isolation ward or hospitalization >48hrs of confirmed COVID-19 positive test. <br/ >5 Patients on ventilator support. <br/ >6 Patients with uncontrolled, unstable comorbidities <br/ >7 Pre-existing or diagnostic history with chronic lung disease, active malignancy, chronic kidney disease, chronic liver disease. <br/ >8 History of allergic reactions or anaphylaxis to investigational product components. <br/ >9 Patients participation in any another study including macro/micro/any other forms of dietary supplements/multivitamins or oral nutrition supplements. <br/ >10 Patients who are Immunocompromised or those on immunosuppressants <br/ >11 Pregnant and lactating females <br/ >12 Any other condition which the principal investigator thinks may jeopardize the safety of subjects.

N/A

N/A

1 Asymptomatic COVID-19 positive patients. <br/ >2 Patient with ordinal scale of â?¥4 <br/ >3 On Tube feeding or parenteral nutrition. <br/ >4 Admission to isolation ward or hospitalization >48hrs of confirmed COVID-19 positive test. <br/ >5 Patients on ventilator support. <br/ >6 Patients with uncontrolled, unstable comorbidities <br/ >7 Pre-existing or diagnostic history with chronic lung disease, active malignancy, chronic kidney disease, chronic liver disease. <br/ >8 History of allergic reactions or anaphylaxis to investigational product components. <br/ >9 Patients participation in any another study including macro/micro/any other forms of dietary supplements/multivitamins or oral nutrition supplements. <br/ >10 Patients who are Immunocompromised or those on immunosuppressants <br/ >11 Pregnant and lactating females <br/ >12 Any other condition which the principal investigator thinks may jeopardize the safety of subjects.

1 Asymptomatic COVID-19 positive patients. <br/ >2 Patient with ordinal scale of â?¥4 <br/ >3 On Tube feeding or parenteral nutrition. <br/ >4 Admission to isolation ward or hospitalization >48hrs of confirmed COVID-19 positive test. <br/ >5 Patients on ventilator support. <br/ >6 Patients with uncontrolled, unstable comorbidities <br/ >7 Pre-existing or diagnostic history with chronic lung disease, active malignancy, chronic kidney disease, chronic liver disease. <br/ >8 History of allergic reactions or anaphylaxis to investigational product components. <br/ >9 Patients participation in any another study including macro/micro/any other forms of dietary supplements/multivitamins or oral nutrition supplements. <br/ >10 Patients who are Immunocompromised or those on immunosuppressants <br/ >11 Pregnant and lactating females <br/ >12 Any other condition which the principal investigator thinks may jeopardize the safety of subjects.